Prospective, multicenter validation of a platform for rapid molecular profiling of central nervous system tumors

Prospective, multicenter validation of a platform for rapid molecular profiling of central nervous system tumors

Molecular data integration plays a central role in central nervous system (CNS) tumor diagnostics but currently used assays pose limitations due to technical complexity, equipment and reagent costs, as well as lengthy turnaround times. We previously reported the development of Rapid-CNS2, an adaptive-sampling-based nanopore sequencing workflow. Here we comprehensively validated and further developed Rapid-CNS2 for intraoperative use. It now offe…

Belay Diagnostics Partners with GenomOncology to Support High-Performance Liquid Biopsy Test for Central Nervous System Cancer Detection

CLEVELAND, March 25, 2025 /PRNewswire/ -- Belay Diagnostics announces its partnership with GenomOncology (GO), a precision medicine software company that provides data-driven tools and resources to improve cancer care. To streamline the tertiary analysis of their Summit™ test, as well…

Nanopore Sequencing Comprehensively Profiles Brain Tumor DNA in 30 Minutes – RamaOnHealthcare

Scientists have unveiled a solution to long-standing challenges in molecular data integration for central nervous system (CNS) tumor diagnostics. A Nature Medicine study introduces a nanopore sequencing workflow called Rapid-CNS2 that delivers real-time tumor classification and DNA insights within just 30 minutes during surgery and comprehensive molecular profiling within 24 hours. Complementing it is MNP-Flex, [...]

Case 2 (cont.)—Metastatic NSCLC With a ROS1 Alteration: Patients With CNS Disease

Panelists discuss the management of metastatic non–-small cell lung cancer (NSCLC) with a ROS1 alteration in patients with central nervous system (CNS) involvement, focusing on treatment strategies and challenges.

Revolution in Brain Cancer Diagnosis: Speed Meets Precision in New Sequencing Technology

The Rapid-CNS2 workflow revolutionizes CNS tumor diagnostics with real-time DNA classification and analysis during surgery. Developed by University Hospital Heidelberg and partners, the method uses nanopore sequencing to significantly reduce diagnostic times from 20 days to less than 2 days. The combination of MinION and GridION devices facilitates urgent tumor insights within 30 minutes and complete profiling in 24 hours. The system accurately …

Nanopore Sequencing Comprehensively Profiles Brain Tumor DNA in 30 Minutes

Scientists have unveiled a solution to long-standing challenges in molecular data integration for central nervous system (CNS) tumor diagnostics. A Nature Medicine study introduces a nanopore sequencing workflow called Rapid-CNS2 that delivers real-time tumor classification and DNA insights within just 30 minutes during surgery and comprehensive molecular profiling within 24 hours. Complementing it is MNP-Flex, a platform-agnostic methylation cl…